Corcept Therapeutics Incorporated - Common Stock (CORT)

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals’ marketing of a generic version of Korlym® does not infringe two of Corcept’s patents concerning methods of safely co-administering Korlym and drugs that inhibit the CYP3A4 enzyme, including drugs that are commonly prescribed to patients with Cushing’s syndrome. The ruling affirms a December 2023 verdict by the Federal District Court for the District of New Jersey.

NEW YORK, NY - February 19, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - February 18, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

NEW YORK, NY - February 17, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - February 14, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - February 13, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).

NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) --

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - February 12, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - February 11, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

LOS ANGELES, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT) for violations of the securities laws.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - February 7, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - February 6, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT).